Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Anda

- PMLiVE

Allergan wins support against dissident shareholders

Shareholders vote on 1 May

- PMLiVE

Teva’s migraine injection approved in Europe

Third anti-CGRP treatment to hit the market

- PMLiVE

Depression drug failure adds to Allergan’s woes

Axe hangs over remaining monotherapy and suicidality trials

- PMLiVE

Teva will have to endure revenue ‘trough’ in 2019

Company looks to migrane treatment Ajovy for growth

- PMLiVE

Industry aghast as EU Parliament backs biosimilar rule change

The change could come into effect in 2021

Generic Differentiation

Even in the cost-led market for generics, differentiated business models evolve

- PMLiVE

Tox trouble stalls Sosei/Allergan Alzheimer’s drug

Surprise findings from primate studies

- PMLiVE

Teva wins FDA OK for crucial migraine drug

Vital to Teva's turnaround, Ajovy will challenge Novartis/Amgen's Aimovig

- PMLiVE

FDA rejects Allergan’s uterine fibroid drug over safety concerns

Its investigational drug has been linked to 'serious' liver damage issues in Europe

Roche's Perjeta pertuzumab

Daily Brief: Biosimilar Herceptin can’t make Perjeta cost effective and more

E-cigarettes can save lives - Teva gains approval for EpiPen generic

- PMLiVE

Regeneron and Teva close gap on rivals with NGF pain drug

Fasinumab was associated with less pain and improved functional ability compared to placebo

- PMLiVE

Industry appointments

Vivaldi heads up Sigilon, Pfizer Oncology loses its CMO and Zelluna appoints new CSO

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links